<DOC>
	<DOCNO>NCT02294344</DOCNO>
	<brief_summary>The clinical efficacy double filtration plasmapheresis ( DFPP ) patient antineutrophil cytoplasmic autoantibody associate glomerulonephritis ( AAGN ) .</brief_summary>
	<brief_title>The Clinical Efficacy DFPP Patients With AAGN</brief_title>
	<detailed_description>This single center , prospective , randomize , control study compare clinical efficacy double filtration plasmapheresis ( DFPP ) combine intravenous cyclophosphamide ( IV-CTX ) pulse therapy versus IV-CTX pulse therapy patient antineutrophil cytoplasmic autoantibody associate glomerulonephritis ( AAGN ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>diagnosis ANCA associate vasculitis ( AAV ) , use criterion adapt disease definition Chapel Hill consensus conference serum positive ANCA ANCA level ≥100 relative unit/ml renal involvement serum creatinine≥3 mg/dl write informed consent provide . secondary vasculitis antiglomerular basement membrane ( GBM ) positive severe infection ; hepatitis B antigenemia , anti hepatitis C virus immunodeficiency ; immunoglobulin G ( IgG ) &lt; 2g/l life threaten renal biopsy show globally sclerotic glomerulus &gt; 60 % normal glomerulus &lt; 10 % need renal replacement therapy 4w receive large dose methylprednisolone ( MP ) , CTX , mycophenolate mofetil ( MMF ) , plasmapheresis intravenous immunoglobulin ( IVIg ) therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>double filtration plasmapheresis</keyword>
	<keyword>ANCA-Associated Vasculitis</keyword>
</DOC>